Alexion Pharmaceuticals is significantly expanding its operations in Ireland by building the US firm’s first ever biologics manufacturing facility outside …

Irish pharma firm Shire has appointed a new chief financial officer and member of its executive committee in Jeff Poulton. …

Takeda will be teaming up with Japan’s National Cancer Center (NCC) to develop new cancer drugs. The two organisations have …

GlaxoSmithKline is boosting its philanthropic efforts in R&D into HIV/AIDS by teaming up with academic researchers to launch a new …

Sandoz the generics division of Novartis has opened a large packaging centre in Stryków in Poland. Valued at 171 million …

Dr Harvey Berger the founder of US pharma firm Ariad Pharmaceuticals has announced his decision to retire as chairman and …

Since being spun-off from GSK and Pfizer, specialist HIV firm ViiV Healthcare has earned the best corporate reputation amongst patients …

Merck will be teaming up with Daiichi Sankyo’s subsidiary Plexxikon to investigate immunotherapy combinations in cancer. A collaborative clinical trial …
Novartis have been temporarily prevented from marketing its biosimilar version of Amgen’s drug Neupogen in the US. Earlier this year …

A new malaria vaccine has shown promise in early stage trials, reducing the risk of contracting the disease by two …

GlaxoSmithKline and Roche have announced the latest changes to its leadership teams as the companies regroup for the year ahead. …

A new smartphone app is able to automatically detect parasites in the blood and may mark a fundamental shift in …

Havas Lynx Group has just bolstered its ranks with the arrival of three new senior appointments. Jon Linscott joins Tim …

Gilead is clearly eyeing a future market involving epigenetics as the US firm buys Danish company EpiTherapeutics for $65 million. …

Johnson & Johnson has struck a ‘first-of-its-kind partnership’ with academic researchers to review requests for compassionate use of its investigational …
Rare disease specialist firm Alexion is splashing out $8.4 billion to buy fellow US orphan drug developer Synageva biopharmaceuticals. The …

Pfizer has confirmed two key appointments to lead its worldwide research and development organisation with immediate effect. The firm will …

Chiesi made its sales reps go through a ‘tick-box’ compliance training exercise to get the pharma industry regulator ‘off its …

Swiss-based Celgene International SÃ rl has appointed Michael Zaiac to the position of vice president of medical affairs for its European haematology …

GlaxoSmithKline’s pharma sales continued to slide in the first quarter of 2015, but ViiV healthcare and the portfolios acquired from …